{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:16:27Z","timestamp":1789600587676,"version":"build-2803163510"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,11,20]],"date-time":"2013-11-20T00:00:00Z","timestamp":1384905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,11,20]],"date-time":"2013-11-20T00:00:00Z","timestamp":1384905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s40259-013-0076-8","type":"journal-article","created":{"date-parts":[[2013,11,19]],"date-time":"2013-11-19T09:26:28Z","timestamp":1384853188000},"page":"75-106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Intravenous Tocilizumab: A Review of Its Use in Adults with Rheumatoid Arthritis"],"prefix":"10.1007","volume":"28","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,20]]},"reference":[{"issue":"9","key":"76_CR1","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College Of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569\u201381.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"76_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.autrev.2004.09.002","volume":"4","author":"Y Alamanos","year":"2005","unstructured":"Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4(3):130\u20136.","journal-title":"Autoimmun Rev."},{"issue":"3","key":"76_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/01.bor.0000218949.19860.d1","volume":"18","author":"N Nishimoto","year":"2006","unstructured":"Nishimoto N. Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol. 2006;18(3):277\u201381.","journal-title":"Curr Opin Rheumatol."},{"issue":"6","key":"76_CR4","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.berh.2010.10.001","volume":"24","author":"L Carmona","year":"2010","unstructured":"Carmona L, Cross M, Williams B, et al. Rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2010;24(6):733\u201345.","journal-title":"Best Pract Res Clin Rheumatol."},{"issue":"3","key":"76_CR5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.semarthrit.2006.08.006","volume":"36","author":"Y Alamanos","year":"2006","unstructured":"Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36(3):182\u20138.","journal-title":"Semin Arthritis Rheum."},{"issue":"23","key":"76_CR6","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205\u201319.","journal-title":"N Engl J Med."},{"key":"76_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/OARRR.S17118","volume":"3","author":"M Mihara","year":"2011","unstructured":"Mihara M, Ohsugi Y, Kishimoto T. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis. Open Access Rheumatol Res Rev. 2011;3:19\u201329.","journal-title":"Open Access Rheumatol Res Rev."},{"issue":"Suppl 1","key":"76_CR8","first-page":"S11","volume":"65","author":"BN Cronstein","year":"2007","unstructured":"Cronstein BN. Interleukin-6: a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65 Suppl 1:S11\u20135.","journal-title":"Bull NYU Hosp Jt Dis."},{"issue":"4","key":"76_CR9","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.V86.4.1243.bloodjournal8641243","volume":"86","author":"T Kishimoto","year":"1995","unstructured":"Kishimoto T, Akira S, Narazaki M, et al. Interleukin-6 family of cytokines and gp130. Blood. 1995;86(4):1243\u201354.","journal-title":"Blood."},{"issue":"5","key":"76_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/09629359890875","volume":"7","author":"T Robak","year":"1998","unstructured":"Robak T, Gladalska A, Stepien H, et al. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm. 1998;7(5):347\u201353.","journal-title":"Mediators Inflamm."},{"issue":"1\u20132","key":"76_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/BF01986402","volume":"41","author":"N Bertazzolo","year":"1994","unstructured":"Bertazzolo N, Punzi L, Stefani MP, et al. Interrelationships between interleukin (IL)-1, IL-6 and IL-8 in synovial fluid of various arthropathies. Agents Actions. 1994;41(1\u20132):90\u20132.","journal-title":"Agents Actions."},{"issue":"6","key":"76_CR12","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/art.1780310614","volume":"31","author":"FA Houssiau","year":"1988","unstructured":"Houssiau FA, Devogelaer JP, Van Damme J, et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988;31(6):784\u20138.","journal-title":"Arthritis Rheum."},{"issue":"3","key":"76_CR13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1136\/ard.52.3.232","volume":"52","author":"R Madhok","year":"1993","unstructured":"Madhok R, Crilly A, Watson J, et al. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52(3):232\u20134.","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"76_CR14","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/rheumatology\/36.12.1298","volume":"36","author":"RH Straub","year":"1997","unstructured":"Straub RH, Muller-Ladner U, Lichtinger T, et al. Decrease of interleukin 6 during the first 12\u00a0months is a prognostic marker for clinical outcome during 36\u00a0months treatment with disease-modifying anti-rheumatic drugs. Br J Rheumatol. 1997;36(12):1298\u2013303.","journal-title":"Br J Rheumatol."},{"issue":"12","key":"76_CR15","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","volume":"5","author":"M Mihara","year":"2005","unstructured":"Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5(12):1731\u201340.","journal-title":"Int Immunopharmacol."},{"issue":"4","key":"76_CR16","first-page":"851","volume":"53","author":"K Sato","year":"1993","unstructured":"Sato K, Tsuchiya M, Saldanha J, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 1993;53(4):851\u20136.","journal-title":"Cancer Res."},{"key":"76_CR17","unstructured":"Genentech Inc. Actemra (tocilizumab): US prescribing information. 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125276s092lbl.pdf. Accessed 8 Nov 2013."},{"key":"76_CR18","unstructured":"European Medicines Agency. Tocilizumab (RoActemra): summary of product characteristics. 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000955\/WC500054890.pdf. Accessed 8 Nov 2013."},{"issue":"5","key":"76_CR19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2165\/00003495-200969050-00007","volume":"69","author":"V Oldfield","year":"2009","unstructured":"Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs. 2009;69(5):609\u201332.","journal-title":"Drugs."},{"issue":"4","key":"76_CR20","first-page":"697","volume":"29","author":"A Snir","year":"2011","unstructured":"Snir A, Kessel A, Haj T, et al. Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy. Clin Exp Rheumatol. 2011;29(4):697\u2013700.","journal-title":"Clin Exp Rheumatol."},{"issue":"11","key":"76_CR21","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s10067-011-1833-z","volume":"30","author":"K Kanbe","year":"2011","unstructured":"Kanbe K, Chen Q, Nakamura A, et al. Inhibition of MAP kinase in synovium by treatment with tocilizumab in rheumatoid arthritis. Clin Rheumatol. 2011;30(11):1407\u201313.","journal-title":"Clin Rheumatol."},{"issue":"7","key":"76_CR22","first-page":"1426","volume":"30","author":"N Nishimoto","year":"2003","unstructured":"Nishimoto N, Yoshizaki K, Maeda K, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis: phase I\/II clinical study. J Rheumatol. 2003;30(7):1426\u201335.","journal-title":"J Rheumatol."},{"issue":"Suppl 1","key":"76_CR23","first-page":"S59","volume":"85","author":"S Grange","year":"2009","unstructured":"Grange S, Kuhn B, Riek M, et al. A randomized, double blind, placebo controlled, parallel group study to investigate the safety, tolerability, and pharmacokinetics of tocilizumab following ascending single dose administration in healthy subjects [abstract no. PII-72]. Clin Pharmacol Ther. 2009;85 Suppl 1:S59.","journal-title":"Clin Pharmacol Ther."},{"issue":"10 Suppl","key":"76_CR24","first-page":"S1076","volume":"64","author":"J Ducreux","year":"2012","unstructured":"Ducreux J, Toukap AN, Houssiau FA, et al. Global molecular effects of tocilizumab therapy in synovial biopsies of early rheumatoid arthritis patients [abstract no. 2548]. Arthritis Rheum. 2012;64(10 Suppl):S1076.","journal-title":"Arthritis Rheum."},{"issue":"10 Suppl","key":"76_CR25","first-page":"51","volume":"63","author":"J Yamana","year":"2011","unstructured":"Yamana J, Iwahashi M, Kim M, et al. T-cell-related cytokines are inhibited in response to tocilizumab in patients with rheumatoid arthritis in contrast with TNF-inhibitor. Arthritis Rheum. 2011;63(10 Suppl):51.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"76_CR26","doi-asserted-by":"publisher","first-page":"279","DOI":"10.7150\/ijbs.5996","volume":"9","author":"G Carbone","year":"2013","unstructured":"Carbone G, Wilson A, Diehl SA, et al. Interleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis. Int J Biol Sci. 2013;9(3):279\u201388.","journal-title":"Int J Biol Sci."},{"issue":"Suppl 3","key":"76_CR27","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/annrheumdis-2013-eular.1348","volume":"72","author":"CI Daien","year":"2013","unstructured":"Daien CI, Gailhac S, Mura T, et al. Tocilizumab increases regulatory T cells and NK cells cytotoxicity in rheumatoid arthritis patients [abstract no. FRI0221]. Ann Rheum Dis. 2013;72 Suppl 3:448.","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"76_CR28","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/art.30242","volume":"63","author":"P Roll","year":"2011","unstructured":"Roll P, Muhammad K, Schumann M, et al. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum. 2011;63(5):1255\u201364.","journal-title":"Arthritis Rheum."},{"key":"76_CR29","first-page":"S575","volume":"64","author":"M Sato","year":"2012","unstructured":"Sato M, Takemura M, Shinohe R, et al. Changes in the levels of anti-cyclic citrullinated protein antibody and immunoglobulins in rheumatoid arthritis patients after administration of tocilizumab [abstract no. 1336]. Arthritis Rheum. 2012;64:S575\u20136.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"76_CR30","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.3899\/jrheum.111439","volume":"39","author":"C Richez","year":"2012","unstructured":"Richez C, Barnetche T, Khoryati L, et al. Tocilizumab: treatment decreases circulating myeloid dendritic cells and monocytes, 2 components of the myeloid lineage. J Rheumatol. 2012;39(6):1192\u20137.","journal-title":"J Rheumatol."},{"key":"76_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-013-2778-0","author":"T Kasama","year":"2013","unstructured":"Kasama T, Isojima S, Umemura M, et al. Serum macrophage migration inhibitory factor levels are correlated with response to tocilizumab therapy in patients with rheumatoid arthritis. Rheumatol Int. 2013. doi:10.1007\/s00296-013-2778-0.","journal-title":"Rheumatol Int."},{"issue":"Suppl 1","key":"76_CR32","first-page":"i92","volume":"52","author":"I Verma","year":"2013","unstructured":"Verma I, Kaur J, Syngle A, et al. Nitric oxide levels in rheumatoid arthritis improves after IL-6 blockade [abstract no. 98]. Rheumatology. 2013;52 Suppl 1:i92\u20133.","journal-title":"Rheumatology."},{"issue":"1","key":"76_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/art.25053","volume":"62","author":"P Garnero","year":"2010","unstructured":"Garnero P, Thompson E, Woodworth T, et al. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum. 2010;62(1):33\u201343.","journal-title":"Arthritis Rheum."},{"key":"76_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.07.008","author":"AC Bay-Jensen","year":"2013","unstructured":"Bay-Jensen AC, Platt A, Byrjalsen I, et al. Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study. Semin Arthritis Rheum. 2013. doi:10.1016\/j.semarthrit.2013.07.008.","journal-title":"Semin Arthritis Rheum."},{"issue":"9","key":"76_CR35","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1007\/s00296-011-2021-9","volume":"32","author":"K Kanbe","year":"2012","unstructured":"Kanbe K, Nakamura A, Inoue Y, et al. Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis. Rheumatol Int. 2012;32(9):2669\u201374.","journal-title":"Rheumatol Int."},{"issue":"10 Suppl","key":"76_CR36","first-page":"1615","volume":"63","author":"S Finzel","year":"2011","unstructured":"Finzel S, Rech J, Schmidt S, et al. Evidence for limited repair of existing bone erosions in rheumatoid arthritis patients treated with the interleukin-6 receptor blocker tocilizumab. Arthritis Rheum. 2011;63(10 Suppl):1615.","journal-title":"Arthritis Rheum."},{"issue":"4","key":"76_CR37","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00296-009-1303-y","volume":"31","author":"S-Y Kawashiri","year":"2011","unstructured":"Kawashiri S-Y, Kawakami A, Yamasaki S, et al. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int. 2011;31(4):451\u20136.","journal-title":"Rheumatol Int."},{"issue":"Suppl 3","key":"76_CR38","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1136\/annrheumdis-2013-eular.2638","volume":"72","author":"K Fragiadaki","year":"2013","unstructured":"Fragiadaki K, Makrilakis K, Smith J, et al. Changes of adipokine serum levels after IL-6 receptor blockade with tocilizumab in patients with rheumatoid arthritis [abstract no. ABO316]. Ann Rheum Dis. 2013;72 Suppl 3:884.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 3","key":"76_CR39","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2013-eular.1259","volume":"72","author":"H Mirjafari","year":"2013","unstructured":"Mirjafari H, Wang J, Klearman M, et al. Insulin resistance is improved by tocilizumab therapy in rheumatoid arthritis: results from the toward study [abstract no. FRI0123]. Ann Rheum Dis. 2013;72 Suppl 3:414.","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"76_CR40","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.3899\/jrheum.110340","volume":"38","author":"K Kume","year":"2011","unstructured":"Kume K, Amano K, Yamada S, et al. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J Rheumatol. 2011;38(10):2169\u201371.","journal-title":"J Rheumatol."},{"issue":"12","key":"76_CR41","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1007\/s00296-011-2135-0","volume":"32","author":"M Hirao","year":"2012","unstructured":"Hirao M, Yamasaki N, Oze H, et al. Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab. Rheumatol Int. 2012;32(12):4041\u20135.","journal-title":"Rheumatol Int."},{"issue":"7","key":"76_CR42","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3899\/jrheum.121389","volume":"40","author":"K Shimamoto","year":"2013","unstructured":"Shimamoto K, Ito T, Ozaki Y, et al. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J Rheumatol. 2013;40(7):1074\u201381.","journal-title":"J Rheumatol."},{"issue":"Suppl 3","key":"76_CR43","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1136\/annrheumdis-2013-eular.1129","volume":"72","author":"N Nishina","year":"2013","unstructured":"Nishina N, Kikuchi J, Hashizume M, et al. Baseline interleukin-6 receptor levels predict the clinical effectiveness of tocilizumab in patients with rheumatoid arthritis [abstract no. FRI0001]. Ann Rheum Dis. 2013;72 Suppl 3:369.","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"76_CR44","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3109\/s10165-009-0203-z","volume":"19","author":"K Funahashi","year":"2009","unstructured":"Funahashi K, Koyano S, Miura T, et al. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level. Mod Rheumatol. 2009;19(5):507\u201312.","journal-title":"Mod Rheumatol."},{"issue":"10 Suppl","key":"76_CR45","first-page":"558","volume":"64","author":"M Kostine","year":"2012","unstructured":"Kostine M, Barnetche T, Ardouin E, et al. Early neutropenia is associated with clinical response in patients receiving tocilizumab in rheumatoid arthritis [abstract no. 1302]. Arthritis Rheum. 2012;64(10 Suppl):558\u2013S9.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 3","key":"76_CR46","first-page":"279","volume":"70","author":"P Emery","year":"2011","unstructured":"Emery P, Bernasconi C, Thompson L. Relationship between pretreatment CRP and clinical efficacy following treatment with tocilizumab: results from a pooled analysis of tocilizumab phase 3 studies [abstract no. THU0305]. Ann Rheum Dis. 2011;70 Suppl 3:279.","journal-title":"Ann Rheum Dis."},{"issue":"10 Suppl","key":"76_CR47","first-page":"912","volume":"64","author":"K Kume","year":"2012","unstructured":"Kume K, Yamada S, Amano K, et al. Anti-cyclic citrullinated protein antibodies as a predictor of response to tocilizumab in patients with rheumatoid arthritis a prospective study [abstract no. 2156]. Arthritis Rheum. 2012;64(10 Suppl):912.","journal-title":"Arthritis Rheum."},{"issue":"Suppl 3","key":"76_CR48","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/annrheumdis-2013-eular.2626","volume":"72","author":"C Casu","year":"2013","unstructured":"Casu C, Bruschi E, Alpini C, et al. Clinical and serological response to tocilizumab in patients with rheumatoid arthritis [abstract no. AB0304]. Ann Rheum Dis. 2013;72 Suppl 3:880.","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"76_CR49","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1007\/s00296-011-2256-5","volume":"32","author":"A Kaneko","year":"2012","unstructured":"Kaneko A, Kida D, Saito K, et al. Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI. Rheumatol Int. 2012;32(11):3631\u20137.","journal-title":"Rheumatol Int."},{"issue":"8","key":"76_CR50","doi-asserted-by":"crossref","first-page":"e003199","DOI":"10.1136\/bmjopen-2013-003199","volume":"3","author":"J Wang","year":"2013","unstructured":"Wang J, Platt A, Upmanyu R, et al. IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis. BMJ Open. 2013;3(8):e003199.","journal-title":"BMJ Open."},{"issue":"5","key":"76_CR51","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3899\/jrheum.110961","volume":"39","author":"B Mesko","year":"2012","unstructured":"Mesko B, Poliska S, Szamosi S, et al. Peripheral blood gene expression and IgG glycosylation profiles as markers of tocilizumab treatment in rheumatoid arthritis. J Rheumatol. 2012;39(5):916\u201328.","journal-title":"J Rheumatol."},{"issue":"12","key":"76_CR52","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1136\/annrheumdis-2012-201950","volume":"71","author":"S Mori","year":"2012","unstructured":"Mori S, Ueki Y, Hirakata N, et al. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis. 2012;71(12):2006\u201310.","journal-title":"Ann Rheum Dis."},{"issue":"8","key":"76_CR53","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/annrheumdis-2012-202658","volume":"72","author":"S Mori","year":"2013","unstructured":"Mori S, Ueki Y, Akeda Y, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis. 2013;72(8):1362\u20136.","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"76_CR54","doi-asserted-by":"publisher","first-page":"648","DOI":"10.5414\/CP201549","volume":"49","author":"S Grange","year":"2011","unstructured":"Grange S, Schmitt C, Banken L, et al. Thorough QT\/QTc study of tocilizumab after single-dose administration at therapeutic and supratherapeutic doses in healthy subjects. Int J Clin Pharmacol Ther. 2011;49(11):648\u201355.","journal-title":"Int J Clin Pharmacol Ther."},{"issue":"7","key":"76_CR55","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1177\/0091270009350623","volume":"50","author":"N Frey","year":"2010","unstructured":"Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol. 2010;50(7):754\u201366.","journal-title":"J Clin Pharmacol."},{"issue":"3","key":"76_CR56","doi-asserted-by":"publisher","first-page":"218","DOI":"10.5414\/CP201613","volume":"50","author":"C Schmitt","year":"2012","unstructured":"Schmitt C, Kuhn B, Zhang X, et al. Tocilizumab has no clinically relevant effects on methotrexate pharmacokinetics in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther. 2012;50(3):218\u201323.","journal-title":"Int J Clin Pharmacol Ther."},{"issue":"5","key":"76_CR57","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/clpt.2011.35","volume":"89","author":"C Schmitt","year":"2011","unstructured":"Schmitt C, Kuhn B, Zhang X, et al. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis [erratum appears in Clin Pharmacol Ther. 2011;90(3):479]. Clin Pharmacol Ther. 2011;89(5):735\u201340.","journal-title":"Clin Pharmacol Ther."},{"issue":"Suppl s1","key":"76_CR58","first-page":"100","volume":"13","author":"K Terao","year":"2010","unstructured":"Terao K, Tsuru T, Suzaki M, et al. Drug-disease interaction study of tocilizumab in patients with rheumatoid arthritis: IL-6 signal inhibition normalized cytochrome P-450 enzymes expression which was reduced by inflammation [abstract no. 0550]. Int J Rheum Dis. 2010;13(Suppl s1):100.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"76_CR59","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/ard.2008.105197","volume":"69","author":"G Jones","year":"2010","unstructured":"Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88\u201396.","journal-title":"Ann Rheum Dis."},{"issue":"9877","key":"76_CR60","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","volume":"381","author":"C Gabay","year":"2013","unstructured":"Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial [errata appear in Lancet 2013;381(9877):1540]. Lancet. 2013;381(9877):1541\u201350.","journal-title":"Lancet."},{"issue":"6","key":"76_CR61","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/art.20303","volume":"50","author":"N Nishimoto","year":"2004","unstructured":"Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50(6):1761\u20139.","journal-title":"Arthritis Rheum."},{"issue":"9","key":"76_CR62","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1002\/art.22033","volume":"54","author":"RN Maini","year":"2006","unstructured":"Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate [erratum appears in Arthritis Rheum. 2008;58(3):887]. Arthritis Rheum. 2006;54(9):2817\u201329.","journal-title":"Arthritis Rheum."},{"issue":"1","key":"76_CR63","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/s10165-008-0125-1","volume":"19","author":"N Nishimoto","year":"2009","unstructured":"Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19(1):12\u20139.","journal-title":"Mod Rheumatol."},{"issue":"9","key":"76_CR64","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/ard.2006.068064","volume":"66","author":"N Nishimoto","year":"2007","unstructured":"Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162\u20137.","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"76_CR65","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/art.30158","volume":"63","author":"JM Kremer","year":"2011","unstructured":"Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63(3):609\u201321.","journal-title":"Arthritis Rheum."},{"issue":"9617","key":"76_CR66","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","volume":"371","author":"JS Smolen","year":"2008","unstructured":"Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987\u201397.","journal-title":"Lancet."},{"issue":"11","key":"76_CR67","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1136\/ard.2008.092932","volume":"67","author":"P Emery","year":"2008","unstructured":"Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial [erratum appears in Ann Rheum Dis. 2009;68(2):296]. Ann Rheum Dis. 2008;67(11):1516\u201323.","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"76_CR68","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/ard.2010.148700","volume":"71","author":"Y Yazici","year":"2012","unstructured":"Yazici Y, Curtis JR, Ince A, et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 2012;71(2):198\u2013205.","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"76_CR69","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"MC Genovese","year":"2008","unstructured":"Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968\u201380.","journal-title":"Arthritis Rheum."},{"issue":"1","key":"76_CR70","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/annrheumdis-2011-201282","volume":"72","author":"M Dougados","year":"2013","unstructured":"Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013;72(1):43\u201350.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 3","key":"76_CR71","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/annrheumdis-2013-eular.245","volume":"72","author":"T Takeuchi","year":"2013","unstructured":"Takeuchi T, Kaneko Y, Atsumi T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in RA patients with inadequate response to methotrexate: 24-week results from a randomized controlled study (SURPRISE study) [abstract no. OP0040]. Ann Rheum Dis. 2013;72 Suppl 3:62.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 1","key":"76_CR72","first-page":"i92","volume":"52","author":"G Jones","year":"2013","unstructured":"Jones G, Sebba A, Lepley D, et al. Long-term efficacy of tocilizumab monotherapy in patients with RA: AMBITION extension 240\u00a0week data [abstract no. 97]. Rheumatology. 2013;52 Suppl 1:i92.","journal-title":"Rheumatology."},{"issue":"10","key":"76_CR73","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2008.092866","volume":"68","author":"N Nishimoto","year":"2009","unstructured":"Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009;68(10):1580\u20134.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 2","key":"76_CR74","first-page":"335","volume":"67","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Hashimoto J, Miyasaka N, et al. Three-year extension of the SAMURAI study confirms tocilizumab to prevent joint destruction in patients with rheumatoid arthritis [abstract no. FRI0153]. Ann Rheum Dis. 2008;67 Suppl 2:335.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"76_CR75","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3109\/s10165-010-0325-3","volume":"21","author":"J Hashimoto","year":"2011","unstructured":"Hashimoto J, Garnero P, van der Heijde D, et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod Rheumatol. 2011;21(1):10\u20135.","journal-title":"Mod Rheumatol."},{"key":"76_CR76","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-013-0894-z","author":"N Nishimoto","year":"2013","unstructured":"Nishimoto N, Amano K, Hirabayashi Y, et al. Drug free REmission\/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol. 2013. doi:10.1007\/s10165-013-0894-z.","journal-title":"Mod Rheumatol."},{"key":"76_CR77","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-013-0895-y","author":"N Nishimoto","year":"2013","unstructured":"Nishimoto N, Amano K, Hirabayashi Y, et al. Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study. Mod Rheumatol. 2013. doi:10.1007\/s10165-013-0895-y.","journal-title":"Mod Rheumatol."},{"key":"76_CR78","unstructured":"SURPRISE Study Group. Success of tocilizumab in rheumatoid arthritis (RA) patients with remission induction and sustained efficacy after discontinuation (SURPRISE) [ClinicalTrials.gov identifier NCT01120366] US National Institutes of Health, ClinicalTrials.gov. 2010. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01120366. Accessed 10 Jul 2013."},{"issue":"10","key":"76_CR79","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1093\/rheumatology\/kes131","volume":"51","author":"V Strand","year":"2012","unstructured":"Strand V, Burmester GR, Ogale S, et al. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology. 2012;51(10):1860\u20139.","journal-title":"Rheumatology."},{"issue":"2","key":"76_CR80","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3899\/jrheum.120447","volume":"40","author":"RM Fleischmann","year":"2013","unstructured":"Fleischmann RM, Halland AM, Brzosko M, et al. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. J Rheumatol. 2013;40(2):113\u201326.","journal-title":"J Rheumatol."},{"issue":"Suppl 3","key":"76_CR81","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1136\/annrheumdis-2012-201615","volume":"72","author":"JM Kremer","year":"2013","unstructured":"Kremer JM, Halland AM, Brozosco M, et al. LITHE: tocilizumab (TCZ) inhibits radiographic progression and improves physical function in patients (pts) with rheumatoid arthritis (RA) at 5\u00a0years with maintenance of clinical efficacy over time. [abstract no. SAT0103 plus poster]. Ann Rheum Dis. 2013;72 Suppl 3:614.","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"76_CR82","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1136\/annrheumdis-2011-200395","volume":"71","author":"JS Smolen","year":"2012","unstructured":"Smolen JS, Avila JCM, Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis. 2012;71(5):687\u201393.","journal-title":"Ann Rheum Dis."},{"issue":"10 Suppl","key":"76_CR83","first-page":"S1077","volume":"64","author":"M Dougados","year":"2012","unstructured":"Dougados M, Kissel K, Conaghan PG, et al. Clinical, radiographic, and immunogenic effects after 1\u00a0year of tocilizumab-based treatment strategy with and without methotrexate in rheumatoid arthritis: the ACT-RAY study. Arthritis Rheum. 2012;64(10 Suppl):S1077\u20138.","journal-title":"Arthritis Rheum."},{"issue":"6","key":"76_CR84","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3899\/jrheum.120687","volume":"40","author":"MC Genovese","year":"2013","unstructured":"Genovese MC, Rubbert-Roth A, Smolen JS, et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6\u00a0years of exposure. J Rheumatol. 2013;40(6):768\u201380.","journal-title":"J Rheumatol."},{"issue":"3","key":"76_CR85","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/s10165-010-0279-5","volume":"20","author":"N Nishimoto","year":"2010","unstructured":"Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol. 2010;20(3):222\u201332.","journal-title":"Mod Rheumatol."},{"issue":"12","key":"76_CR86","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1136\/annrheumdis-2011-201087","volume":"71","author":"VP Bykerk","year":"2012","unstructured":"Bykerk VP, Ostor AJK, Alvaro-Gracia J, et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and\/or TNF inhibitors: a large, open-label study close to clinical practice. Ann Rheum Dis. 2012;71(12):1950\u20134.","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"76_CR87","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/acr.21847","volume":"65","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt ME, Kremer J, Cush J, et al. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study. Arthritis Care Res. 2013;65(3):362\u201371.","journal-title":"Arthritis Care Res."},{"issue":"5","key":"76_CR88","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1136\/ard.2010.139725","volume":"70","author":"GR Burmester","year":"2011","unstructured":"Burmester GR, Feist E, Kellner H, et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24\u00a0weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis. 2011;70(5):755\u20139.","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"76_CR89","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1093\/rheumatology\/ker221","volume":"50","author":"T Takeuchi","year":"2011","unstructured":"Takeuchi T, Tanaka Y, Amano K, et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients: REACTION\u00a052-week study. Rheumatology. 2011;50(10):1908\u201315.","journal-title":"Rheumatology."},{"issue":"10 Suppl","key":"76_CR90","first-page":"2629","volume":"63","author":"H Yamanaka","year":"2011","unstructured":"Yamanaka H, Harigai M, Inokuma S, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan full analysis report of 7,901 patients [abstract]. Arthritis Rheum. 2011;63(10 Suppl):2629.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"76_CR91","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/ard.2011.149765","volume":"70","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology\/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70(3):404\u201313.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 3","key":"76_CR92","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/annrheumdis-2013-eular.201","volume":"72","author":"M Genovese","year":"2013","unstructured":"Genovese M, Sebba A, Rubbert-Roth A, et al. Long-term safety of tocilizumab in patients with rheumatoid arthritis following a mean treatment duration of 3.9\u00a0years [abstract no. FRI0256 plus poster presentation]. Ann Rheum Dis. 2013;72 Suppl 3:461.","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"76_CR93","doi-asserted-by":"publisher","first-page":"R141","DOI":"10.1186\/ar3455","volume":"13","author":"MH Schiff","year":"2011","unstructured":"Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13(5):R141.","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"76_CR94","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3109\/s10165-011-0488-6","volume":"22","author":"D Hoshi","year":"2012","unstructured":"Hoshi D, Nakajima A, Inoue E, et al. Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab. Mod Rheumatol. 2012;22(1):122\u20137.","journal-title":"Mod Rheumatol."},{"issue":"12","key":"76_CR95","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1136\/ard.2011.151092","volume":"70","author":"T Koike","year":"2011","unstructured":"Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis. 2011;70(12):2148\u201351.","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"76_CR96","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"JA Singh","year":"2012","unstructured":"Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625\u201339.","journal-title":"Arthritis Care Res."},{"issue":"6","key":"76_CR97","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964\u201375.","journal-title":"Ann Rheum Dis."},{"key":"76_CR98","unstructured":"European League Against Rheumatism. EULAR issues updated rheumatoid arthritis (RA) management recommendations [media release]. 3 July 2013. http:\/\/www.eular.org\/myUploadData\/files\/EULAR%20RA%20recommendations%20FINAL.pdf."},{"issue":"4","key":"76_CR99","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1136\/annrheumdis-2012-202469","volume":"72","author":"JS Smolen","year":"2013","unstructured":"Smolen JS, Schoels MM, Nishimoto N, et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis. 2013;72(4):482\u201392.","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"76_CR100","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1177\/1759720X10384434","volume":"2","author":"A Balsa","year":"2010","unstructured":"Balsa A, Garcia-Arias M. Is there a place for nonbiological drugs in the treatment of rheumatoid arthritis? Therapeutic advances in musculoskeletal disease. 2010;2(6):307\u201313.","journal-title":"Therapeutic advances in musculoskeletal disease."},{"issue":"6","key":"76_CR101","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1136\/ard.2003.011395","volume":"63","author":"FC Breedveld","year":"2004","unstructured":"Breedveld FC, Kalden JR. Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis. 2004;63(6):627\u201333.","journal-title":"Ann Rheum Dis."},{"issue":"13 Suppl","key":"76_CR102","first-page":"S303","volume":"18","author":"A Gibofsky","year":"2012","unstructured":"Gibofsky A. Comparative effectiveness of current treatments for rheumatoid arthritis. Am J Manag Care. 2012;18(13 Suppl):S303\u201314.","journal-title":"Am J Manag Care."},{"issue":"Suppl 6","key":"76_CR103","doi-asserted-by":"crossref","first-page":"vi37","DOI":"10.1093\/rheumatology\/kes283","volume":"51","author":"EM Ruderman","year":"2012","unstructured":"Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology. 2012;51 Suppl 6:vi37\u201343.","journal-title":"Rheumatology."},{"issue":"8","key":"76_CR104","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3899\/jrheum.110207","volume":"39","author":"VP Bykerk","year":"2012","unstructured":"Bykerk VP, Akhavan P, Hazlewood GS, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol. 2012;39(8):1559\u201382.","journal-title":"J Rheumatol."},{"key":"76_CR105","unstructured":"National Institute of Health and Care Excellence. Tocilizumab for the treatment of rheumatoid arthritis (rapid review of technology appraisal guidance 198). 2012. http:\/\/www.nice.org.uk\/nicemedia\/live\/13669\/58202\/58202.pdf. Accessed 14 Aug 2013."},{"issue":"4","key":"76_CR106","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3109\/s10165-009-0197-6","volume":"19","author":"R Koike","year":"2009","unstructured":"Koike R, Harigai M, Atsumi T, et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol. 2009;19(4):351\u20137.","journal-title":"Mod Rheumatol."},{"issue":"4","key":"76_CR107","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3109\/s10165-010-0402-7","volume":"21","author":"S-Y Kawashiri","year":"2011","unstructured":"Kawashiri S-Y, Kawakami A, Iwamoto N, et al. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index. Mod Rheumatol. 2011;21(4):365\u20139.","journal-title":"Mod Rheumatol."},{"key":"76_CR108","unstructured":"National Institute of Health and Care Excellence. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor. 2009. http:\/\/www.nice.org.uk\/nicemedia\/live\/13108\/50413\/50413.pdf. Accessed 15 Aug 2013."},{"issue":"2","key":"76_CR109","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/0091270012437585","volume":"53","author":"M Levi","year":"2013","unstructured":"Levi M, Grange S, Frey N. Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis. J Clin Pharmacol. 2013;53(2):151\u20139.","journal-title":"J Clin Pharmacol."},{"issue":"9877","key":"76_CR110","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/S0140-6736(13)60634-0","volume":"381","author":"S De Vita","year":"2013","unstructured":"De Vita S. Tocilizumab versus adalimumab for rheumatoid arthritis. Lancet. 2013;381(9877):1515\u20137.","journal-title":"Lancet."},{"issue":"3","key":"76_CR111","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3109\/s10165-011-0528-2","volume":"22","author":"T Kojima","year":"2012","unstructured":"Kojima T, Kaneko A, Hirano Y, et al. Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice. Mod Rheumatol. 2012;22(3):370\u20135.","journal-title":"Mod Rheumatol."},{"key":"76_CR112","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-012-0822-7","author":"Y Kawasaki","year":"2013","unstructured":"Kawasaki Y, Hashimoto T, Okano T, et al. Shorter disease duration is important for tocilizumab to achieve Boolean remission. Mod Rheumatol. 2013. doi:10.1007\/s10165-012-0822-7.","journal-title":"Mod Rheumatol."},{"key":"76_CR113","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-012-0825-4","author":"D Hoshi","year":"2013","unstructured":"Hoshi D, Nakajima A, Shidara K, et al. Disability is the major negative predictor for achievement of Boolean-based remission in patients with rheumatoid arthritis treated with tocilizumab. Mod Rheumatol. 2013. doi:10.1007\/s10165-012-0825-4.","journal-title":"Mod Rheumatol."},{"issue":"9 Suppl B","key":"76_CR114","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.18553\/jmcp.2011.17.s9-b.S14","volume":"17","author":"SK Agarwal","year":"2011","unstructured":"Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J Manage Care Pharm. 2011;17(9 Suppl B):S14\u20138.","journal-title":"J Manage Care Pharm"},{"issue":"12","key":"76_CR115","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1002\/acr.21764","volume":"64","author":"JR Curtis","year":"2012","unstructured":"Curtis JR, Lanas A, John A, et al. Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. Arthritis Care Res. 2012;64(12):1819\u201328.","journal-title":"Arthritis Care Res."},{"issue":"Suppl 1","key":"76_CR116","doi-asserted-by":"publisher","first-page":"i104","DOI":"10.1136\/ard.2010.140145","volume":"70","author":"SI Grivennikov","year":"2011","unstructured":"Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis. 2011;70 Suppl 1:i104\u20138.","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"76_CR117","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","volume":"9","author":"PA van Schouwenburg","year":"2013","unstructured":"van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(3):164\u201372.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"76_CR118","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","volume":"72","author":"FB Vincent","year":"2013","unstructured":"Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72(2):165\u201378.","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"76_CR119","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3111\/13696998.2011.649327","volume":"15","author":"EJ Soini","year":"2012","unstructured":"Soini EJ, Hallinen TA, Puolakka K, et al. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ. 2012;15(2):340\u201351.","journal-title":"J Med Econ."},{"issue":"3","key":"76_CR120","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3111\/13696998.2012.665110","volume":"15","author":"A Diamantopoulos","year":"2012","unstructured":"Diamantopoulos A, Benucci M, Capri S, et al. Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy. J Med Econ. 2012;15(3):576\u201385.","journal-title":"J Med Econ."},{"issue":"Suppl 1","key":"76_CR121","first-page":"i84","volume":"52","author":"D Harland","year":"2012","unstructured":"Harland D, Gibbons C, Pang H, et al. Tocilizumab in methotrexate-intolerant or contraindicated patients: a cost-utility model for the United Kingdom [abstract no. 78]. Rheumatology. 2012;52 Suppl 1:i84.","journal-title":"Rheumatology."},{"issue":"Suppl 3","key":"76_CR122","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/annrheumdis-2012-eular.2871","volume":"71","author":"C Gibbons","year":"2012","unstructured":"Gibbons C, Diamantopoulos A, Pang H. Tocilizumab in methotrexate-intolerant or contraindicated patients: a cost-utility model for Scotland [abstract no. FRI0414]. Ann Rheum Dis. 2012;71 Suppl 3:454.","journal-title":"Ann Rheum Dis."},{"issue":"10 Suppl","key":"76_CR123","first-page":"S1037","volume":"64","author":"JJ Carlson","year":"2012","unstructured":"Carlson JJ, Ogale S, Dejonckheere F, et al. Cost-effectiveness of tocilizumab monotherapy vs adalimumab monotherapy in the treatment of severe active rheumatoid arthritis [abstract no. 2463]. Arthritis Rheum. 2012;64(10 Suppl):S1037\u2013S8.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 3","key":"76_CR124","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/annrheumdis-2012-eular.528","volume":"71","author":"E Tanaka","year":"2012","unstructured":"Tanaka E, Inoue E, Hoshi D, et al. Cost-effectiveness of a humanized anti-interleukin-6 (Il-6) receptor monoclonal antibody, tocilizumab, in rheumatoid arthritis using IORRA cohort database [abstract no. AB0528]. Ann Rheum Dis. 2012;71 Suppl 3:668.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 3","key":"76_CR125","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2013-eular.22","volume":"72","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Rigby W, van Vollenhoven R, et al. Tocilizumab (TCZ) in combination and monotherapy versus methotrexate (MTX) in methotrexate-naive patients (PTS) with early rheumatoid arthritis (RA): clinical and radiographic outcomes from a randomized placebo-controlled trial [abstract no. OP0041 plus oral presentation]. Ann Rheum Dis. 2013;72 Suppl 3:63.","journal-title":"Ann Rheum Dis."},{"key":"76_CR126","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203523","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis. 2013. doi:10.1136\/annrheumdis-2013-203523.","journal-title":"Ann Rheum Dis."},{"key":"76_CR127","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22110","author":"A Ogata","year":"2013","unstructured":"Ogata A, Tanimura K, Sugimoto T, et al. A phase 3 study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis (MUSASHI). Arthritis Care Res. 2013. doi:10.1002\/acr.22110 (Accepted article).","journal-title":"Arthritis Care Res."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-013-0076-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-013-0076-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-013-0076-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-013-0076-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T21:18:42Z","timestamp":1746047922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-013-0076-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,20]]},"references-count":127,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["76"],"URL":"https:\/\/doi.org\/10.1007\/s40259-013-0076-8","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,20]]},"assertion":[{"value":"20 November 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}